VIENNA, Va., APRIL 24 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION , a developer of immune-system based treatments for cancer and infectious diseases, announces that two of its key scientists have published an important article in the April issue of The Scientist, a leading scientific publication. In this article, Dr. Zimmerman and Dr. Talor of CEL-SCI, along with Dr. Rosenthal, Professor of Microbiology and Immunology at Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, propose several new approaches to boost vaccine development and R&D for vaccines, a huge US and global health care issue. The article can be found on the web at http://www.the-scientist.com and is entitled “The Vaccine Conundrum”.
Dr. Zimmerman is the developer of CEL-SCI’s CEL-1000 product which is being tested as a potential adjuvant to enhance the effectiveness of vaccines. Dr. Talor is the developer of the Company’s Multikine technology which is cleared for Phase III clinical trials in head & neck cancer in the US and Canada.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company’s lead product Multikine(R) is cleared to enter a global Phase III clinical trial in advanced primary head and neck cancer patients in the U.S. and Canada. CEL-SCI’s other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
CEL-SCI Corporation
CONTACT: Gavin de Windt of CEL-SCI, +1-703-506-9460, fax, +1-703-506-9471
